raseglurant raseglurant raseglurant (inn) (code name adx-10059) is a negative allosteric modulator of the mglu5 receptor and derivative of mpep which was under development by addex therapeutics for the treatment of migraine, gastroesophageal reflux disease, and dental anxiety. it reached phase ii clinical trials for all of the aforementioned indications before being discontinued due to the observation of possible predictive signs of hepatotoxicity in patients with long-term use. raseglurantclinical dataatc codenoneidentifiers iupac name 2--4,6-dimethyl-3-pyridinamine cas number757950-09-7pubchem cid10331863chemspider8507323unii66ucj8z8l1comptox dashboard (epa)dtxsid40226707 chemical and physical dataformulac15h13fn2molar mass240.281 g·mol−13d model (jsmol)interactive image smiles fc2cccc(c#cc1nc(cc(c1n)c)c)c2 inchi inchi=1s/c15h13fn2/c1-10-8-11(2)18-14(15(10)17)7-6-12-4-3-5-13(16)9-12/h3-5,8-9h,17h2,1-2h3key:medclnyiyberko-uhfffaoysa-n